|
Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >
Risk factor analysis for taxane-associated acute pain syndrome under the dexamethasone prophylaxis
| Title: | Risk factor analysis for taxane-associated acute pain syndrome under the dexamethasone prophylaxis |
| Authors: | Saito, Yoshitaka Browse this author →KAKEN DB | | Takekuma, Yoh Browse this author →KAKEN DB | | Kobayashi, Masaki Browse this author →KAKEN DB | | Sakamoto, Tatsuhiko Browse this author | | Yamashita, Hiroko Browse this author →KAKEN DB | | Sugawara, Mitsuru Browse this author →KAKEN DB |
| Keywords: | Taxane-associated acute pain syndrome (T-APS) | | Paclitaxel | | Docetaxel | | Dexamethasone (DEX) | | Arthralgia | | Myalgia |
| Issue Date: | 6-Jul-2021 |
| Publisher: | Springer |
| Journal Title: | Supportive care in cancer |
| Volume: | 29 |
| Start Page: | 8059 |
| End Page: | 8067 |
| Publisher DOI: | 10.1007/s00520-021-06342-2 |
| Abstract: | Purpose Taxane-associated acute pain syndrome (T-APS) reportedly occurs in approximately 70% of patients undergoing therapy. We have previously reported that additional dexamethasone (DEX) administration attenuates T-APS. The aim of this study was to reveal risk factor(s) associated with the incidence of T-APS under prophylactic DEX administration. Methods In total, 143 patients with breast cancer who received docetaxel (75 mg/m(2)) or paclitaxel (175 mg/m(2))-containing treatment regimens were enrolled. DEX (4-8 mg) was orally administered on days 2-4. Risk factors for the incidence of >= G2 and all-grade T-APS, as well as T-APS incidence between taxane-containing regimens in the first cycle, were retrospectively evaluated. Results Approximately 90% of the patients received taxanes for adjuvant or neoadjuvant chemotherapy. Overall, 55% of patients administered 4 mg DEX, whereas 45% received 8 mg DEX. Pegfilgrastim was administered in 27% of patients. Incidence of >= G2 and all-grade T-APS was 23.8%, and 69.2%, respectively. Univariate and multivariate analyses revealed that administration of pegfilgrastim is an independent risk factor for the incidence of >= G2 and all-grade T-APS; age younger than 55 years is also a risk factor for all-grade T-APS. Moreover, the incidence of >= G2 and all-grade T-APS was 45.5% and 81.8% in a paclitaxel regimen, and 22.0% and 68.2% in docetaxel-including regimens, respectively, revealing increased tendency with paclitaxel administration, with no significant differences. Conclusion Pegfilgrastim co-administration is an independent risk factor for >= G2 and all-grade T-APS, and age younger than 55 years is a risk factor of all-grade T-APS under prophylactic DEX administration. |
| Rights: | This is a post-peer-review, pre-copyedit version of an article published in Supportive care in cancer. The final authenticated version is available online at: http://dx.doi.org/10.1007/s00520-021-06342-2 |
| Type: | article (author version) |
| URI: | http://hdl.handle.net/2115/86277 |
| Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
Submitter: 齋藤 佳敬
|
